Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28971975 | 0.79 | CES2 (0.41) | CYP2D6KMT2ACES2CES1SRC | |
| SCHEMBL3955535 | 0.78 | CYP2D6 (0.42) | CYP2D6KMT2ACES2CES1SRC | |
| SCHEMBL858 | 0.78 | CYP2D6 (0.42) | CYP2D6KMT2ASRCTSHRLMNA | |
| Hydrochloric Acid SCHEMBL10708013 | 0.76 | HTT (0.44) | CYP2D6KMT2ATSHRLMNAMAPK1 | |
| SCHEMBL1156574 | 0.74 | TSHR (0.44) | CYP2D6KMT2ASRCDPP4F2 | |
| SCHEMBL12555585 | 0.74 | CYP2D6 (0.44) | CYP2D6KMT2ACES2CES1SRC | |
| SCHEMBL7052526 | 0.74 | CYP2D6 (0.39) | CYP2D6KMT2ACES2CES1SRC | |
| SCHEMBL15181483 | 0.74 | DPP4 (0.44) | CYP2D6KMT2ADPP4F2GLS | |
| SCHEMBL959684 | 0.74 | DPP4 (0.44) | CYP2D6KMT2ADPP4F2GLS | |
| SCHEMBL4386400 | 0.74 | KMT2A (0.42) | CYP2D6KMT2ASRCDPP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199106-B2 | Lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199105-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7164011-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1654268-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1644393-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1529052-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012320-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005007665-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
| WO-2004016632-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | CYP2D6 2219/4885KMT2A 3959/4885CES2 442/4885 |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | LCLAT1, NRDC, LAS1L | CYP2D6 2845/4885KMT2A 3761/4885CES2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.